Abstract: A method for providing tests and measurements using a transceiver is disclosed. In some examples, the method may involve using, at least one test instrument and at least one transceiver, to perform tests and measurements at a testing point in a network. The tests and measurements may include at least one of: (1) channel or wavelength and data measurements; (2) insertion loss and optical power measurements; or (3) bit error rate (BER) measurements.

Abstract: A method for providing tests and measurements using a transceiver is disclosed. In some examples, the method may involve using, at least one test instrument and at least one transceiver, to perform tests and measurements at a testing point in a network. The tests and measurements may include at least one of: (1) channel or wavelength and data measurements; (2) insertion loss and optical power measurements; or (3) bit error rate (BER) measurements.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A method for providing tests and measurements using a transceiver is disclosed. In some examples, the method may involve using, at least one test instrument and at least one transceiver, to perform tests and measurements at a testing point in a network. The tests and measurements may include at least one of: (1) channel or wavelength and data measurements; (2) insertion loss and optical power measurements; or (3) bit error rate (BER) measurements.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: Systems and methods for providing peak current mode control (PCMC) for power converters using discrete analog components. A pair of complementary bipolar junction transistors may be used to set a maximum duty cycle for the power converter. PCMC may be achieved using a comparator that compares peak input current to an error feedback signal and terminates a pulse-width modulation (PWM) pulse when the peak input current exceeds the error feedback signal. A magnetic signal transformer may be used to establish a secondary side bias voltage supply, to return the error signal, and to drive an AC-coupled signal for a synchronous gate drive. A synchronous switch may be turned on when the main switch is turned off via an output winding of the flyback transformer and may be turned off by the trailing edge of a clock pulse from the magnetic signal transformer before the main switch is turned on.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: Systems and methods for providing a self-driven synchronous rectification circuit for an active-clamp forward converter which includes automatically enhancing synchronous MOSFETs and maximizing input voltage range. The gate signals for the synchronous MOSFETs are derived from a unipolar magnetic coupling signal instead of a bipolarized magnetic coupling signal. The unipolar signal is retained for fully enhanced driving of the MOSFETs at low line voltage and the unipolar signal is automatically converted to a bipolar signal at high line amplitude due to line variance to maximize input voltage range by utilizing non-polarized characteristics of the MOSFET gate-to-source voltage (Vgs). The circuit permits efficient scaling for higher output voltages such as 12 volts DC or 15 volts DC, without requiring extra windings on the transformer of the forward converter.